Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 18/20 | 0.65 |
| ▸ | PDE4B | Q07343 | 18/20 | 0.65 |
| ▸ | PDE4C | Q08493 | 18/20 | 0.65 |
| ▸ | PDE4D | Q08499 | 18/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 14/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4038586 | 0.91 | PDE4A (0.60) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4036083 | 0.86 | PDE4A (0.69) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL6634880 | 0.83 | PDE4A (0.58) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL6182890 | 0.80 | PDE4A (0.84) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL6183408 | 0.80 | CYP2C9 (0.82) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL6182833 | 0.79 | PDE4A (0.71) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL6183888 | 0.79 | CYP2C9 (1.00) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL6181589 | 0.79 | PDE4A (0.66) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL6182869 | 0.79 | PDE4A (0.73) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL6180648 | 0.79 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1487797-B1 | HETERO-BRIDGE SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2009-05-27 | — | — | EP | disclosed |
| US-7144896-B2 | Hetero-bridge substituted 8-arylquinoline pde4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2006-12-05 | — | — | US | disclosed |
| US-20050245513-A1 | Hetero-bridge substituted 8-arylquinoline pde4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2005-11-03 | — | — | US | disclosed |
| EP-1487797-A1 | HETERO-BRIDGE SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS | Merck Frosst Canada & Co. (CA) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003078397-A1 | HETERO-BRIDGE SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245513-A1 | Hetero-bridge substituted 8-arylquinoline pde4 inhibitors | PDE4A, PDE4B, PDE4C | PDE4A 1/4885PDE4B 2/4885PDE4C 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.